Short answer
TuHURA Biosciences, Inc./NV (HURA) filed its Q3 2025 10-Q quarterly report on Nov 14, 2025 for the quarter ended Sep 30, 2025. Quarterly revenue was $0 with net income of −$7M.
Q3 2025 key financials · XBRL
- Revenue
- $0
- Net income
- −$7M
- +25.4% QoQ
- EPS (diluted)
- −$0.14
- +33.3% QoQ
Source: XBRL data from the TuHURA Biosciences, Inc./NV (HURA) Q3 2025 10-Q on SEC EDGAR. USD.
TuHURA Biosciences, Inc./NV Q3 2025 10-Q analysis
AI summary of MD&A and risk factor updates
Risk Factors
- New risk added: clinical hold lifted by FDA for Phase 3 trial of IFx-2.0 triggered milestone-based private placement funding of $12.6M in June 2025
- Material update: Kineta Merger closed June 30, 2025, adding TBS-2025 asset and changing product pipeline and operational scope significantly
- Regulatory risk: reliance on FDA’s accelerated approval pathway for IFx-2.0 Phase 3 Merkel cell carcinoma trial initiated June 2025
- Operational risk: increased research and development expenses to $14.5M for 9M 2025 from $9.4M in prior year, driven by clinical and personnel cost rises
- Financial risk: cash and cash equivalents at $2.7M as of September 30, 2025, with a $3M secured promissory note facility maturing December 31, 2025
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other TuHURA Biosciences, Inc./NV quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.